

Design of Selective Inhibitors for ARTD10 in an Interdisciplinary Approach

Daniela Meister¹, Patricia Verheugd², Julien Engel³, Valeria Losasso⁴, Arno Claßen¹, Bernhard Lüscher², Giulia Rossetti^{5,6,7} and Carsten Bolm¹

¹Institute of Organic Chemistry, RWTH Aachen University, Landoltweg 1, 52074 Aachen, Germany. ²Institute of Biochemistry and Molecular Biology, Medical School, RWTH Aachen University, Pauwelsstraße 30, 52074 Aachen, Germany. ³Cardiff University, School of Chemistry, Main Building, Park Place, Cardiff, CF10 3AT, United Kingdom. ⁴Scientific Computing Department, STFC Daresbury Laboratory, Daresbury, Warrington, WA4 4AD, United Kingdom. ⁵Department of Oncology, Hematology and Stem Cell Transplantation, Medical School, RWTH Aachen University, Pauwelsstraße 30, 52074 Aachen, Germany. ⁶IAS-5/INM-9: Institute for Advanced Simulation/Institute of Neuroscience and Medicine, Forschungszentrum Jülich, 52425 Jülich, Germany. ⁷Jülich Supercomputing Centre, Forschungszentrum Jülich, 52425 Jülich, Germany. daniela.meister@rwth-aachen.de

The enzyme ARTD10 is a member of the ADP-ribosyltransferase family (ARTDs) and performs mono-ADP-ribosylation (MARylation).^[1,2] In this post-translational modification it transfers the ADP-ribose moiety of NAD⁺ on substrate proteins. Since ARTD10 participates in DNA repair, intracellular signaling and interacts with cMyc, it became a target of inhibitor development in the last years.^[3,4,5] In general, most ARTD inhibitors are derived from the unselective inhibitor 3-aminobenzamide.^[6,7] For example, the inhibitor OUL35, which is selective for ARTD10 and in the focus of our research, consists of two benzamide parts.^[8] Here we present the results of *in silico*, *in vitro* and *in cell* experiments on potential ARTD10 inhibitors. Furthermore, we draw a comparison between our suggested ARTD10 inhibitors and OUL35. Overall, we show how computational, organic and biochemistry can work together for the development and the characterization of potential inhibitors for ARTD10.

1. K. L. H. Feijs, P. Verheugd, B. Lüscher, *Febs J.* **2013**, *280*, 3519.
2. H. Kleine, E. Poreba, K. Lesniewicz, P. O. Hassa, M. O. Hottiger, D. W. Litchfield, B. H. Silton, B. Lüscher, *Mol. Cell* **2008**, *32*, 57.
3. M. Bütepage, L. Ecke, P. Verheugd, B. Lüscher, *Cells* **2015**, *4*, 569 and references herein.
4. R. K. Morgan, I. Carter-O'Connell, M. S. Cohen, *Bioorg. Med. Chem. Lett.* **2015**, *25*, 4770.
5. T. Ekblad, A. E. G. Lindgren, C. D. Andersson, R. Caraballo, A.-G. Thorsell, T. Karlberg, S. Spjut, A. Linusson, H. Schüler, M. Elofsson, *Eur. J. Med. Chem.* **2015**, *95*, 546.
6. M. R. Purnell, W. J. D. Whish, *Biochem. J.* **1980**, *185*, 775.
7. E. Wahlberg, T. Karlberg, E. Kouznetsova, N. Markova, A. Macchiarulo, A.-G. Thorsell, E. Pol, Å. Frostell, T. Ekblad, D. Öncü, B. Kull, G. M. Robertson, R. Pellicciari, H. Schüler, J. Weigelt, *Nat. Biotech.* **2012**, *30*, 283.
8. H. Venkannagari, P. Verheugd, J. Koivunen, T. Haikarainen, E. Obaji, Y. Ashok, M. Narwal, T. Pihlajaniemi, B. Lüscher, L. Lethiö, *Cell Chemical Biology* **2016**, *23*, 1251.